Ambroxol HCL Raw Material Powder

Product Name: Ambroxol HCL Raw Material Powder

CAS: 23828-92-4

MF: C13H19Br2ClN2O

Specification​: 99% min Ambroxol HCL Powder

Sample:  Ambroxol HCL Powder

Keywords: Ambroxol HCL Raw Material Powder,Ambroxol HCL Powder,Ambroxol HCL Powder Supplier

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Ambroxol HCL Powder Usage and Synthesis:

Ambroxol Hydrochloride (Ambroxol Hydrochloride) is the active metabolite of the expectorant bromhexine (N-demethylation, trans-hydroxyl is introduced into the para-position of the cyclohexyl group), its toxicity is lower than that of bromhexine, and its activity is higher than that of bromhexine . Ambroxol HCL Powder can improve expectoration, and has the effect of promoting pulmonary surfactant and airway secretion and cilia movement. Clinically, Ambroxol HCL Powder can regulate the secretion of mucus and mucus, activate the vibration of cilia, easily dilute sputum, strengthen the outward transport of mucus, and make it easy to discharge. Ambroxol HCL Powder can also promote the synthesis of pulmonary surfactant to maintain alveolar tension and ensure Lung function index; promote the penetration of antibiotics into the tissue to increase the concentration and enhance the bactericidal effect; anti-oxidation, reduce the release of inflammatory mediators, so as to alleviate the inflammatory response.

Pharmacokinetics of Ambroxol HCL Powder:
Ambroxol hydrochloride mainly acts on the secretory cells of the respiratory tract, regulates the secretion of mucus and serous substances, increases the secretion of serous substances, and can also crack the polysaccharide fibers of acidic glycoproteins in sputum, and inhibit the acidic proteins in mucous glands and goblet cells. Synthesis of sputum, reducing the viscosity of sputum, making sputum thin and easy to discharge; at the same time, the drug can also increase the frequency and intensity of movement of respiratory cilia, promote sputum discharge and self-purification of the respiratory tract. Ambroxol hydrochloride has obvious antioxidant effect, and plays an important role in the pulmonary diseases of reactive free oxygen groups.

Clinical Application of Ambroxol HCL Powder:
1. Application in respiratory system
Ambroxol hydrochloride can increase the secretion of serous fluid in the airway, dilute the sputum and make it easy to discharge, thereby improving the respiratory condition and enabling the PS of the respiratory mucosa to play a normal protective role; at the same time, it also has a high affinity for the lungs, which can promote lung Synthesis and secretion of PS to maintain alveolar stability, which is conducive to the improvement of alveolar function. Therefore, early application of ambroxol hydrochloride can relieve airway obstruction, improve ventilation, shorten the course of disease, and reduce various complications. It is often used in the treatment of chronic bronchitis exacerbation, asthmatic bronchitis, pneumonia, and lung abscess.
2. Application in senile chronic obstructive pulmonary disease (COPD)
COPD is a common disease of the respiratory tract. With the increase of age, the clearance function of airway cilia in the elderly gradually declines, and the antioxidant effect of the lungs decreases. Ambroxol has anti-inflammatory, anti-oxidation and increased ciliary movement, which can improve the clearance function of the airway epithelial surface, thereby preventing The occurrence of COPD.
3. Clinical application in neonatal respiratory system
Neonatal respiratory distress syndrome (NRDS) is caused by pulmonary surfactant (PS) deficiency. Ambroxol can promote the synthesis and secretion of endogenous PS, increase the release of endogenous PS from alveolar type II cells, thereby reducing the surface tension of the alveoli, reinflating the atrophied alveoli, thereby improving lung function and shortening the duration of mechanical ventilation. Time and oxygen therapy time, reduce the high risk factors of bronchopneumonia.
4. Lung protection after cardiopulmonary bypass (CPB)
Cardiopulmonary bypass lung injury is the most common complication after cardiothoracic surgery. Foreign studies have confirmed that after CPB, the lung undergoes ischemia-reperfusion injury, neutrophils and platelets are activated, accumulate in the lung, attach to the inner wall of the pulmonary capillary, release a large number of oxygen free radicals and inflammatory mediators, and damage alveolar type II cells and blood vessels Endothelial cells, resulting in decreased release of PS synthesis. In addition, the permeability of the alveolar-capillary membrane increases, the fluid in the alveoli accumulates, and the excessive consumption of PS cannot exert normal physiological effects, which increases the surface tension of the alveoli and tends to collapse the alveoli, resulting in respiratory disorders. Ambroxol hydrochloride can effectively promote the synthesis and secretion of PS after thoracic surgery, inhibit the activated neutrophil reaction, reduce airway resistance and airway hyperresponsiveness, affect airway wall ion transport and potential difference, and reduce the risk of cardiopulmonary bypass. posterior lung injury.